Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood (2025) 146 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2025-1042

Published: 2025

Journal Articles

An update: Safety and efficacy of GPRC5D targeting CAR-T cell therapy in relapsed/refractory multiple myeloma patients

Shiqi Li, Yongwei Zheng, Zhongtao Yuan, Lin Liu, Yu Li, Xiaoping Li, Yingnian Chen, Qingying Zang, Lihua Zhang, Mengli Xu, Ping Yin, Lvzhe Chen, Guangchao Li, Wen Ding, Kaikai Zeng, Donghui Ma, Chunfu Li, Min Luo, Sanbin Wang

Blood (2025) 146 (Supplement 1): 5854.

https://doi.org/10.1182/blood-2025-5854

Published: 2025

Journal Articles

Autologous CD19-directed CAR-T exhibit promising safety and efficacy in refractory primary immune thrombocytopenia

Blood (2025) 146 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2025-4175

Published: 2025

Journal Articles

A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

Blood (2024) 144 (Supplement 1): 378.

https://doi.org/10.1182/blood-2024-204984

Published: 2024

Journal Articles

Safety and Efficacy of GPRC5D CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients

Shiqi Li, Zhongtao Yuan, Lin Liu, Yu Li, Le Luo, Yingnian Chen, Lihua Zhang, Guangchao Li, Min Luo, Kaikai Zeng, Donghui Ma, Sanbin Wang, Sr.

Blood (2023) 142 (Supplement 1): 3472.

https://doi.org/10.1182/blood-2023-179147

Published: 2023

Journal Articles

Venetoclax Plus Azacitidine, Low Dose Cytarabine, Aclarubicin and G-CSF (VA-CAG Regimen) for Newly Diagnosed Young Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase 2 Clinical Trial

Xiaoping Li, Xiaoyan Li, Yanling Jin, Zucong Chen, Yonglin Shen, Zhongtao Yuan, Lin Liu, Yu Li, Le Luo, Shiqian Hou, Chaoyang Zhou, Chie Qiu, Kui Zhang, Chunfu Li, Yang Liang, Sanbin Wang, Sr.

Blood (2023) 142 (Supplement 1): 834.

https://doi.org/10.1182/blood-2023-174469

Published: 2023

Journal Articles

Phase II Multicenter, Randomized Controlled Study on Infusion of MSCs at 45 Days after Haplo-Hematopoietic Stem Cell Transplantation in the Prophylaxis of Gvhd

Ruihao Huang, Ting Chen, Sanbin Wang, Jishi Wang, Yi Su, Jing Liu, Peiyan Kong, Cheng Zhang, Lei Gao, Li Gao, Xi Zhang

Blood (2022) 140 (Supplement 1): 7651–7652.

https://doi.org/10.1182/blood-2022-169431

Published: 2022

Journal Articles

Fludarabine, Busulfan and Melphalan Based Conditioning Reduced Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myeloid Malignancies: A Multicenter Retrospective Analysis

Jieling Jiang, Sanbin Wang, Xiaojin WU, Xiao Lin Yin, Xiaofan Li, Dong Wu, Quanyi Lu, Kourong Miao, Houcai Wang, Jiong Hu

Blood (2022) 140 (Supplement 1): 10465–10466.

https://doi.org/10.1182/blood-2022-166286

Published: 2022

Journal Articles

A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma

Hua Zhang, Lei Gao, Li Liu, Jishi Wang, PhD, Sanbin Wang, Li Gao, Cheng Zhang, MD PhD, Yao Liu, Peiyan Kong, Jia Liu, Jiaping He, Yu Han, Hua Shi, Yan He, Xun Ye, Yi Zhao, Wei Cao, Lianjun Shen, Xi Zhang

Blood (2019) 134 (Supplement_1): 3147.

https://doi.org/10.1182/blood-2019-131056

Published: 2019

Journal Articles

CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside

Cheng Zhang, Jiaping He, Li Liu, Jishi Wang, PhD, Sanbin Wang, Ligen Liu, Lei Gao, Li Gao, Yao Liu, Peiyan Kong, Jia Liu, Yu Han, Yongliang Zhang, Zhe Sun, Xun Ye, Yan He, Lianjun Shen, MD PhD, Wei Cao, Xi Zhang

Blood (2019) 134 (Supplement_1): 1340.

https://doi.org/10.1182/blood-2019-128006

Published: 2019

Journal Articles

A Double Priming Induction Regimen for Acute Myeloid Leukemia with Inferior PS Among Resource Limited Areas

Stephen Liang, MD, Siliang Chen, Xiaoli Huang, Zheyuan Qin, Sanbin Wang

Blood (2018) 132 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2018-99-118732

Published: 2018

Journal Articles

A Refined Regimen for Maximally Eliminating Early Life-Threatening Complications for Patients with High-Risk Acute Promyelocytic Leukemia

Sanbin Wang, Lihui Peng, Lin Liu, Le Luo, Stephen Liang, MD

Blood (2018) 132 (Supplement 1): 3994.

https://doi.org/10.1182/blood-2018-99-118620

Published: 2018

Journal Articles

Outcome of Ruxolitinib and Sirolimus in Preventing aGVHD Post to HLA Matched Hemotopietic Stem Cell Transplantation

Sanbin Wang, Xiaoli Huang, Lin Liu, Yang Liang

Blood (2018) 132 (Supplement 1): 5727.

https://doi.org/10.1182/blood-2018-99-119109

Published: 2018

Journal Articles

Tandem Autologous Hematopoietic Stem Cell Transplantation Treatment for Adult T-Cell Lymphoblastic Lymphoma: A Multiple Center Prospective Study in Southwestern China

Blood (2018) 132 (Supplement 1): 5747.

https://doi.org/10.1182/blood-2018-99-115705

Published: 2018

Journal Articles

Sirolimus Is Effective in Refractory Immune Thrombocytopenia: Results of an Open-Label Prospective Multicenter Trial in China

Blood (2017) 130 (Supplement 1): 4728.

https://doi.org/10.1182/blood.V130.Suppl_1.4728.4728

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

An update: Safety and efficacy of GPRC5D targeting CAR-T cell therapy in relapsed/refractory multiple myeloma patients

Autologous CD19-directed CAR-T exhibit promising safety and efficacy in refractory primary immune thrombocytopenia

A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia

Safety and Efficacy of GPRC5D CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients

Venetoclax Plus Azacitidine, Low Dose Cytarabine, Aclarubicin and G-CSF (VA-CAG Regimen) for Newly Diagnosed Young Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase 2 Clinical Trial

Phase II Multicenter, Randomized Controlled Study on Infusion of MSCs at 45 Days after Haplo-Hematopoietic Stem Cell Transplantation in the Prophylaxis of Gvhd

Fludarabine, Busulfan and Melphalan Based Conditioning Reduced Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myeloid Malignancies: A Multicenter Retrospective Analysis

A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma

CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside

A Double Priming Induction Regimen for Acute Myeloid Leukemia with Inferior PS Among Resource Limited Areas

A Refined Regimen for Maximally Eliminating Early Life-Threatening Complications for Patients with High-Risk Acute Promyelocytic Leukemia

Outcome of Ruxolitinib and Sirolimus in Preventing aGVHD Post to HLA Matched Hemotopietic Stem Cell Transplantation

Tandem Autologous Hematopoietic Stem Cell Transplantation Treatment for Adult T-Cell Lymphoblastic Lymphoma: A Multiple Center Prospective Study in Southwestern China

Sirolimus Is Effective in Refractory Immune Thrombocytopenia: Results of an Open-Label Prospective Multicenter Trial in China

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only